These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38750568)

  • 1. Retention of people who inject drugs enrolled in a 'medications for opioid use disorder' (MOUD) programme in Uganda.
    Mudiope P; Mutamba BB; Komuhangi L; Nangendo J; Alamo S; Mathers B; Makumbi F; Wanyenze R
    Addict Sci Clin Pract; 2024 May; 19(1):39. PubMed ID: 38750568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections.
    Ivasiy R; Madden LM; DiDomizio E; Johnson KA; Machavariani E; Ahmad B; Oliveros D; Ram A; Kil N; Altice FL
    Drug Alcohol Depend; 2024 Oct; 263():112410. PubMed ID: 39159600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of methadone providers under counterfactual scenarios.
    Tatara E; Lin Q; Ozik J; Kolak M; Collier N; Halpern D; Anselin L; Dahari H; Boodram B; Schneider J
    PLoS Comput Biol; 2024 Jul; 20(7):e1012307. PubMed ID: 39058746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.
    Button D; Cook R; King C; Khuyen TT; Kunkel L; Bart G; Thuy DT; Nguyen DB; Blazes CK; Giang LM; Korthuis PT
    Int J Drug Policy; 2022 Feb; 100():103503. PubMed ID: 34768124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections.
    Marks LR; Munigala S; Warren DK; Liss DB; Liang SY; Schwarz ES; Durkin MJ
    J Infect Dis; 2020 Sep; 222(Suppl 5):S513-S520. PubMed ID: 32877547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities.
    Handanagic S; Broz D; Finlayson T; Kanny D; Wejnert C;
    Drug Alcohol Depend; 2024 Apr; 257():111251. PubMed ID: 38457965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of emergency guidance to the COVID-19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine.
    Ivasiy R; Madden LM; Meteliuk A; Machavariani E; Ahmad B; Zelenev A; Desai MM; Bromberg DJ; Polonsky M; Galvez de Leon SJ; Farnum SO; Islam Z; Altice FL
    Addiction; 2024 Sep; 119(9):1585-1596. PubMed ID: 38807448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study.
    Hayashi K; Ti L; Ayutthaya PPN; Suwannawong P; Kaplan K; Small W; Kerr T
    Harm Reduct J; 2017 Sep; 14(1):63. PubMed ID: 28882155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
    Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
    JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam.
    King C; Cook R; Giang LM; Bart G; Hoffman K; Waddell EN; Korthuis PT
    J Subst Abuse Treat; 2022 Mar; 134():108451. PubMed ID: 33962813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting 6-month retention among people with opioid use disorders accessing outpatient methadone maintenance therapy in Tshwane, South Africa.
    Gloeck NR; Harris BN; Webb EM; Scheibe A
    S Afr Med J; 2020 Dec; 111(1):68-73. PubMed ID: 33404009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to retention in medications for opioid use disorder treatment in real-world practice.
    Villamil VI; Underwood N; Cremer LJ; Rooks-Peck CR; Jiang X; Guy GP
    J Subst Use Addict Treat; 2024 May; 160():209310. PubMed ID: 38331319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network centrality and HIV prevention service use among people who inject drugs: Findings from a sociometric network cohort in New Delhi, India.
    Prata Menezes N; Mehta SH; Wesolowski A; Clipman SJ; Srikrishnan AK; Kumar MS; Zook KJC; Lucas GM; Latkin C; Solomon SS
    Addiction; 2024 Mar; 119(3):570-581. PubMed ID: 37967827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.